Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Licenses Methylation Technology to Takara

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today said that it has licensed to Takara Bio non-exclusive worldwide rights to its methylation-specific PCR technology.

Japan-based Takara has licensed the technology for the scientific research market. In exchange, MDxHealth will receive an upfront fee and royalties on sales of products incorporating the MSP technology. The firms did not disclose additional terms.

MDxHealth is based in Liege, Belgium, and formerly operated under the name OncoMethylome Sciences. The firm plans to leverage its methylation platform to develop DNA-based assays, which will then be offered through CLIA-certified laboratories in the US.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.